Clarity Secures Large-Scale Cu-64 Supply Agreement with Theragenics

Clarity Pharmaceuticals’ announcement of a large-scale manufacturing supply agreement with Theragenics for copper-64 (Cu-64) represents a pivotal moment in the commercial de-risking of its Targeted Copper Theranostics (TCT) platform. While the radiopharmaceutical sector has seen a surge in interest—evidenced by multi-billion dollar acquisitions by Eli Lilly and Bristol Myers Squibb—the primary hurdle remains the complex logistics of isotope production and distribution. By securing a long-term, high-volume supply of Cu-64, Clarity is addressing the logistical bottleneck of the industry: the short half-life of traditional diagnostic isotopes.

The strategic choice of Cu-64 is central to Clarity’s competitive advantage. Most current PET imaging agents rely on Gallium-68 (Ga-68) or Fluorine-18 (F-18), which possess half-lives of approximately 68 minutes and 110 minutes, respectively. These constraints necessitate on-site cyclotrons or very local distribution, often leading to scheduling difficulties and high waste. In contrast, Cu-64’s 12.7-hour half-life allows for centralized manufacturing and nationwide shipping. This agreement with Theragenics, a leader in isotope production, ensures that Clarity can scale its diagnostic products, such as SAR-bisPSMA for prostate cancer, to meet the demands of large-scale Phase 3 clinical trials and eventual commercial use.

“

Clarity Pharmaceuticals’ announcement of a large-scale manufacturing supply agreement with Theragenics for copper-64 (Cu-64) represents a pivotal moment in the commercial de-risking of its Targeted Copper Theranostics (TCT) platform.

Theragenics brings significant technical infrastructure to the partnership. As a veteran in the medical isotope space, their ability to produce high-purity Cu-64 at scale is a critical validation of Clarity’s supply chain strategy. This partnership likely involves dedicated cyclotron capacity, ensuring that Clarity is not subject to the spot-market volatility or supply disruptions that have plagued other radiopharmaceutical developers. For Theragenics, the deal solidifies their position as a key enabler in the next generation of theranostic agents, moving beyond traditional brachytherapy seeds into the high-growth area of systemic radioligand therapy.

From a clinical perspective, the security of isotope supply is a prerequisite for regulatory approval. The FDA and other global regulators require evidence of a robust and reproducible manufacturing process before granting marketing authorization. By locking in Theragenics as a primary supplier, Clarity is effectively building the chemistry, manufacturing, and controls (CMC) package required for its lead candidates. This is particularly relevant for the SAR-bisPSMA program, which has shown promising results in detecting prostate cancer lesions that were missed by conventional Ga-68 PSMA-11 imaging.